Investors
Invest in InDex
Pharmaceuticals
-
InDex Pharmaceuticals’ investor call at 15:00 CET on June 1
May 31, 2023 Non Regulatory
-
InDex Pharmaceuticals announces license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan
May 31, 2023 Regulatory
InDex Pharmaceuticals published the interim report for Q1 2023 on May 24, 2023.
-
Interim Report Q2 2023
-
Interim Report Q3 2023
-
Year-end Report 2023
InDex Pharmaceuticals in numbers
-
15-30
The most common age of an ulcerative colitis diagnosis
-
2 Million
Patients living with ulcerative colitis in the US and Europe
-
7.5 billion USD
Total yearly sales of medications for ulcerative colitis
-
12 billion USD
The estimated total yearly sales of medication for ulcerative colitis in 2026
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis.
Investor contact
